Literature DB >> 33846504

Patient-derived organoids as a predictive biomarker for treatment response in cancer patients.

G Emerens Wensink1, Sjoerd G Elias2, Jasper Mullenders3, Miriam Koopman1, Sylvia F Boj3, Onno W Kranenburg4,5, Jeanine M L Roodhart6.   

Abstract

Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 17 publications have examined PDOs as a potential predictive biomarker in the treatment of cancer patients. We review and provide a pooled analysis of the results regarding the use of PDOs in individualized tumour response testing, focusing on evidence for analytical validity, clinical validity and clinical utility. We identify future perspectives to accelerate the implementation of PDOs as a predictive biomarker in the treatment of cancer patients.

Entities:  

Year:  2021        PMID： 33846504     DOI： 10.1038/s41698-021-00168-1

Source DB:  PubMed          Journal:  NPJ Precis Oncol        ISSN： 2397-768X


  36 in total

Review 1.  The third dimension bridges the gap between cell culture and live tissue.

Authors:  Francesco Pampaloni; Emmanuel G Reynaud; Ernst H K Stelzer
Journal:  Nat Rev Mol Cell Biol       Date:  2007-10       Impact factor: 94.444

2.  Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium.

Authors:  Toshiro Sato; Daniel E Stange; Marc Ferrante; Robert G J Vries; Johan H Van Es; Stieneke Van den Brink; Winan J Van Houdt; Apollo Pronk; Joost Van Gorp; Peter D Siersema; Hans Clevers
Journal:  Gastroenterology       Date:  2011-09-02       Impact factor: 22.682

Review 3.  Organoids - Preclinical Models of Human Disease.

Authors:  Mo Li; Juan C Izpisua Belmonte
Journal:  N Engl J Med       Date:  2019-02-07       Impact factor: 91.245

4.  Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology.

Authors:  Richard Simon
Journal:  Per Med       Date:  2010-01-01       Impact factor: 2.512

5.  The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.

Authors:  D L van der Velden; L R Hoes; H van der Wijngaart; J M van Berge Henegouwen; E van Werkhoven; P Roepman; R L Schilsky; W W J de Leng; A D R Huitema; B Nuijen; P M Nederlof; C M L van Herpen; D J A de Groot; L A Devriese; A Hoeben; M J A de Jonge; M Chalabi; E F Smit; A J de Langen; N Mehra; M Labots; E Kapiteijn; S Sleijfer; E Cuppen; H M W Verheul; H Gelderblom; E E Voest
Journal:  Nature       Date:  2019-09-30       Impact factor: 49.962

Review 6.  The cancer biomarker problem.

Authors:  Charles L Sawyers
Journal:  Nature       Date:  2008-04-03       Impact factor: 49.962

7.  Functional precision cancer medicine-moving beyond pure genomics.

Authors:  Anthony Letai
Journal:  Nat Med       Date:  2017-09-08       Impact factor: 53.440

Review 8.  Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018.

Authors:  J Ferlay; M Colombet; I Soerjomataram; T Dyba; G Randi; M Bettio; A Gavin; O Visser; F Bray
Journal:  Eur J Cancer       Date:  2018-08-09       Impact factor: 9.162

9.  Prospective derivation of a living organoid biobank of colorectal cancer patients.

Authors:  Marc van de Wetering; Hayley E Francies; Joshua M Francis; Gergana Bounova; Francesco Iorio; Apollo Pronk; Winan van Houdt; Joost van Gorp; Amaro Taylor-Weiner; Lennart Kester; Anne McLaren-Douglas; Joyce Blokker; Sridevi Jaksani; Sina Bartfeld; Richard Volckman; Peter van Sluis; Vivian S W Li; Sara Seepo; Chandra Sekhar Pedamallu; Kristian Cibulskis; Scott L Carter; Aaron McKenna; Michael S Lawrence; Lee Lichtenstein; Chip Stewart; Jan Koster; Rogier Versteeg; Alexander van Oudenaarden; Julio Saez-Rodriguez; Robert G J Vries; Gad Getz; Lodewyk Wessels; Michael R Stratton; Ultan McDermott; Matthew Meyerson; Mathew J Garnett; Hans Clevers
Journal:  Cell       Date:  2015-05-07       Impact factor: 41.582

10.  Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Authors:  Georgios Vlachogiannis; Somaieh Hedayat; Alexandra Vatsiou; Yann Jamin; Javier Fernández-Mateos; Khurum Khan; Andrea Lampis; Katherine Eason; Ian Huntingford; Rosemary Burke; Mihaela Rata; Dow-Mu Koh; Nina Tunariu; David Collins; Sanna Hulkki-Wilson; Chanthirika Ragulan; Inmaculada Spiteri; Sing Yu Moorcraft; Ian Chau; Sheela Rao; David Watkins; Nicos Fotiadis; Maria Bali; Mahnaz Darvish-Damavandi; Hazel Lote; Zakaria Eltahir; Elizabeth C Smyth; Ruwaida Begum; Paul A Clarke; Jens C Hahne; Mitchell Dowsett; Johann de Bono; Paul Workman; Anguraj Sadanandam; Matteo Fassan; Owen J Sansom; Suzanne Eccles; Naureen Starling; Chiara Braconi; Andrea Sottoriva; Simon P Robinson; David Cunningham; Nicola Valeri
Journal:  Science       Date:  2018-02-23       Impact factor: 47.728
View more
  28 in total

Review 1.  Clinical relevance of tumour-associated macrophages.

Authors:  Mikael J Pittet; Olivier Michielin; Denis Migliorini
Journal:  Nat Rev Clin Oncol       Date:  2022-03-30       Impact factor: 66.675

2.  Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report.

Authors:  Marie-Anne Meier; Sandro Nuciforo; Mairene Coto-Llerena; John Gallon; Matthias S Matter; Caner Ercan; Jürg Vosbeck; Luigi M Terracciano; Savas D Soysal; Daniel Boll; Otto Kollmar; Raphaël Delaloye; Salvatore Piscuoglio; Markus H Heim
Journal:  Commun Med (Lond)       Date:  2022-07-01

3.  Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems.

Authors:  Yi Wei; Bastian Amend; Tilman Todenhöfer; Nizar Lipke; Wilhelm K Aicher; Falko Fend; Arnulf Stenzl; Niklas Harland
Journal:  Int J Mol Sci       Date:  2022-06-04       Impact factor: 6.208

4.  A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal Cancer.

Authors:  Ulrike Pfohl; Jürgen Loskutov; Sanum Bashir; Ralf Kühn; Patrick Herter; Markus Templin; Soulafa Mamlouk; Sergei Belanov; Michael Linnebacher; Florian Bürtin; Marcus Vetter; Christoph Reinhard; Lena Wedeken; Christian R A Regenbrecht
Journal:  Cancers (Basel)       Date:  2022-07-01       Impact factor: 6.575

Review 5.  Technologies to Assess Drug Response and Heterogeneity in Patient-Derived Cancer Organoids.

Authors:  Melissa C Skala; Dustin A Deming; Jeremy D Kratz
Journal:  Annu Rev Biomed Eng       Date:  2022-03-08       Impact factor: 11.324

Review 6.  Engineering complexity in human tissue models of cancer.

Authors:  Kacey Ronaldson-Bouchard; Ilaria Baldassarri; Daniel Naveed Tavakol; Pamela L Graney; Maria Samaritano; Elisa Cimetta; Gordana Vunjak-Novakovic
Journal:  Adv Drug Deliv Rev       Date:  2022-03-09       Impact factor: 17.873

Review 7.  Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review).

Authors:  Yagmur Sisman; Tine Schnack; Estrid Høgdall; Claus Høgdall
Journal:  Mol Clin Oncol       Date:  2021-12-10

Review 8.  Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy.

Authors:  Jingjing Qu; Farhin Shaheed Kalyani; Li Liu; Tianli Cheng; Lijun Chen
Journal:  Cancer Commun (Lond)       Date:  2021-10-29

9.  RNA sequencing of long-term label-retaining colon cancer stem cells identifies novel regulators of quiescence.

Authors:  Joseph L Regan; Dirk Schumacher; Stephanie Staudte; Andreas Steffen; Ralf Lesche; Joern Toedling; Thibaud Jourdan; Johannes Haybaeck; Dominik Mumberg; David Henderson; Balázs Győrffy; Christian R A Regenbrecht; Ulrich Keilholz; Reinhold Schäfer; Martin Lange
Journal:  iScience       Date:  2021-05-24

10.  The somatic molecular evolution of cancer: Mutation, selection, and epistasis.

Authors:  Krishna Dasari; Jason A Somarelli; Sudhir Kumar; Jeffrey P Townsend
Journal:  Prog Biophys Mol Biol       Date:  2021-08-06       Impact factor: 4.799
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.